News | Heart Valve Technology | April 20, 2017

Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation

New guidelines offer clear recommendations for treating a complicated condition about which limited long-term data exist

Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation

April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even mild ischemic mitral regurgitation (IMR) has been linked to increased long-term mortality. How best to treat IMR is controversial, in part, because of the fragility and complexity of the patients, difficulty of grading IMR, the variety of medical and surgical options, and lack of long-term quality studies. Noting that other guidelines generally do not focus on optimal surgical approaches to IMR, the American Association for Thoracic Surgery (AATS) enlisted a group of experts to create a consensus document to provide clinicians with their recommendations based on their opinions and the best available evidence. The Guidelines are published in The Journal of Thoracic and Cardiovascular Surgery, the official publication of the AATS.

“We acknowledge that ischemic MR remains a challenging situation for the clinician and surgeon. However, emerging data has provided an opportunity for more guided recommendations for this patient population. These guidelines will continue to evolve as more data is reported in the future,” commented Irving L. Kron, M.D., professor of surgery at the University of Virginia School of Medicine and chair of the AATS IMR Consensus Guidelines Writing Committee.

An example of what the guidelines offer is a section on whether to repair or replace the mitral valve in severe IMR – a very controversial issue. While guidelines from the American Heart Association/American College of Cardiology and the European Society of Cardiology/European Association for CardioThoracic Surgery recommend mitral valve surgery for patients with severe IMR who remain symptomatic despite optimal medical treatment, they “provide no guidance in selecting MV replacement versus MV repair,” explained Kron.

These new guidelines suggest that replacement for patients with severe IMR who have a basal aneurysm (dyskinesis), significant echocardiographic evidence of leaflet tethering, or moderate to severe left ventricular remodeling (left ventricular end-diastolic diameter >65mm) is a reasonable therapy. Repair, rather than replacement, can also be considered for those who do not have a basal aneurysm/dyskinesis, significant leaflet tethering or severe LV enlargement.

For patients with moderate IMR, these guidelines say MV repair can be considered at the time of coronary artery bypass grafting. Coronary bypass alone is usually sufficient. Additional sections of the document are devoted to optimizing IMR imaging and whether to use percutaneous transcatheter MV repair.

Mitral regurgitation is blood leakage through the mitral valve into the left atrium. It can be the result of damage to the valve itself or ischemic damage to left ventricular heart muscle, for example following myocardial infarction. IMR can lead to elevated left atrial blood pressure and volume, pulmonary hypertension and fluid build-up in the lungs. Patients with IMR can experience chest pain and palpitations, shortness of breath, fatigue, weakness, lightheadedness, and swelling of the ankles, feet and abdomen, and the possibility of heart failure, atrial fibrillation and death.

“These guidelines reflect the efforts of a panel of experts, drawing on expert opinion among other modalities, and are based on what we know at this time,” remarked Kron. “There is no doubt that the guidelines will continue to evolve as reports of longer-term follow-up emerge.”

Read the full guidelines here.

For more information: www.aats.org


Related Content

News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
News | Heart Valve Technology

Jan. 25, 2025—A new study presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that ...

Home January 27, 2025
Home
Subscribe Now